Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals Digital PIC

Insilico Medicine and MobiDrop Sign Strategic Partnership to Advance AI‑Ready Single‑Cell Data for Drug Discovery

Fineline Cube Sep 7, 2026
Company PIC

Innovent Biologics’ Suzhou Base Passes EMA On‑Site Inspection, Securing EU GMP Certification on First Attempt

Fineline Cube Sep 7, 2026
Company Drug PIC

Santen’s Atropine Eye Drops RYJUSEA Wins NDA Acceptance From China’s NMPA for Myopia Progression

Fineline Cube Sep 7, 2026
Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Drug

NMPA Accepts MediLink Therapeutics’ NDA for Tam‑Peli, Self‑Developed B7‑H3‑Targeting ADC for Relapsed Small Cell Lung Cancer

Fineline Cube Sep 7, 2026
Company Drug

CSPC SYH2069 GLP-1/GIP Dual Agonist Wins FDA Nod for Obesity

Fineline Cube Dec 8, 2025

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2069 Injection, its GLP-1/GIP receptor dual-biased agonist...

Company Drug

Asieris APL-1401 Ulcerative-Colitis Phase 1b Data Positive

Fineline Cube Dec 8, 2025

Asieris Pharmaceuticals (SHA: 688176) presented Phase 1b trial data for APL-1401 in moderate-to-severe active ulcerative...

Company Medical Device

Balance Medical ePTFE Pericardial-Membrane Gets NMPA Nod, Ends Import Reliance

Fineline Cube Dec 8, 2025

Beijing Balance Medical Technology Co., Ltd. (SHA: 688198) announced that its expanded polytetrafluoroethylene (ePTFE) pericardial...

Company Deals

Shanghai Pharma X842 Deal Termination with Sinorda

Fineline Cube Dec 8, 2025

Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607, SHA: 601607) announced the termination of its...

Company Drug

Weixikang Lidocaine-Tetracaine Cream NMPA Clinical Trial Approval

Fineline Cube Dec 8, 2025

Tibet Weixikang Pharmaceutical Co., Ltd. (SHA: 603676) announced that its lidocaine-tetracaine cream has received approval...

Company Drug

Anke-Biotech PA3-17 CAR-T Pediatric Indication NMPA Accepted

Fineline Cube Dec 8, 2025

Anhui Anke Biotechnology (Group) Co., Ltd. (SHE: 300009) announced that the China National Medical Products...

Company Deals Medical Device

Mirxes XtalPi AI Platform Targets Asian GI Cancers

Fineline Cube Dec 8, 2025

Mirxes Holding Company Limited (HKG: 2629) announced it has entered into a memorandum of understanding...

Company Deals Drug

Sirnaomics ChemPartner GalAhead Nucleic-Acid Deal

Fineline Cube Dec 8, 2025

Sirnaomics Ltd. (HKG: 2257) announced a global non‑exclusive licensing agreement with ChemPartner Co., Ltd. (SHE:...

Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Fineline Cube Dec 8, 2025

The National Healthcare Security Administration (NHSA) released the 2025 National Medical Insurance Drug List and...

Company Deals

OTR Therapeutics Series-A Raises $100M for Neurology Pipeline

Fineline Cube Dec 8, 2025

OTR Therapeutics Limited announced the successful completion of a USD 100 million Series A financing,...

Company Deals

Sanofi Completes Vicebio $1.6B Acquisition, Adds RSV Vaccine Platform

Fineline Cube Dec 5, 2025

Sanofi (NASDAQ: SNY) announced the completion of its $1.6 billion acquisition of Vicebio, first announced in...

Company Drug

Juventas CAR-T LBCL Launch Marks Second Indication

Fineline Cube Dec 5, 2025

Juventas Cell Therapy Ltd announced the commercial launch of inaticabtagene autoleucel for relapsed or refractory...

Company Drug

BMS Breyanzi MZL FDA Approval First CAR-T

Fineline Cube Dec 5, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) announced that the FDA has approved Breyanzi (lisocabtagene maraleucel; liso-cel)...

Company Deals

Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient

Fineline Cube Dec 5, 2025

Formosa Pharmaceuticals, Inc. (TPE: 6838) announced an exclusive licensing agreement with Rxilient Medical Pte. Ltd.,...

Company Drug

Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint

Fineline Cube Dec 4, 2025

Novo Nordisk (NYSE: NVO) reported at the Clinical Trials on Alzheimer’s Disease conference that semaglutide...

Company Medical Device

Acotec V-otter Microcatheter Secures NMPA Approval for TACE Procedures

Fineline Cube Dec 4, 2025

Acotec Scientific Holdings Limited (HKG: 6669) announced it has received registration approval from China’s National...

Company Deals

Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes

Fineline Cube Dec 4, 2025

Youjia Biomedical Technology and Hangzhou Tongee Medical Technology Co., Ltd officially signed a strategic cooperation...

Company Drug

Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod

Fineline Cube Dec 4, 2025

Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that its FXS0887 tablet has...

Company Drug

TransThera Tinengotinib Cholangiocarcinoma Priority Review China

Fineline Cube Dec 4, 2025

TransThera Sciences (Nanjing) Inc. (HKG: 2617) announces that Tinengotinib tablets have been included in the...

Company Deals R&D

Bio-Sincerity UCAS R&D Center Pharma Synthesis

Fineline Cube Dec 4, 2025

Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (SHE: 301096) announced the signing of a cooperation agreement with...

Posts pagination

1 … 122 123 124 … 717

Recent updates

  • HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems
  • NMPA Accepts MediLink Therapeutics’ NDA for Tam‑Peli, Self‑Developed B7‑H3‑Targeting ADC for Relapsed Small Cell Lung Cancer
  • Insilico Medicine and MobiDrop Sign Strategic Partnership to Advance AI‑Ready Single‑Cell Data for Drug Discovery
  • Innovent Biologics’ Suzhou Base Passes EMA On‑Site Inspection, Securing EU GMP Certification on First Attempt
  • Santen’s Atropine Eye Drops RYJUSEA Wins NDA Acceptance From China’s NMPA for Myopia Progression
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Company Drug

NMPA Accepts MediLink Therapeutics’ NDA for Tam‑Peli, Self‑Developed B7‑H3‑Targeting ADC for Relapsed Small Cell Lung Cancer

Company Deals Digital PIC

Insilico Medicine and MobiDrop Sign Strategic Partnership to Advance AI‑Ready Single‑Cell Data for Drug Discovery

Company PIC

Innovent Biologics’ Suzhou Base Passes EMA On‑Site Inspection, Securing EU GMP Certification on First Attempt

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.